Solventum Corp (SOLV) Upgraded to a ‘Buy’ at Argus Research

Solventum Corporation (NYSE:SOLV) is one of the 15 successful spin-off companies. On July 1, analysts at Argus Research upgraded the company to a ‘Buy’ from a Hold.’ The analysts also reiterated a $90 price target on the stock. The adjustment comes amid growing confidence that the company is enjoying robust growth.

Solventum Corp (SOLV) Upgraded to a ‘Buy’ at Argus Research

A healthcare professional in a meeting with a patient discussing care options using digital technology.

The upgrade underscores Argus Research’s confidence in Solventum Corp’s ability to execute its long-range plan. The firm expects the company to achieve its margin and revenue targets. In addition, the research firm cited the company’s higher-margin business as one of the reasons behind the upgrade.

Consequently, the research firm has raised its adjusted earnings estimate for the company’s 2026 fiscal year from $5.95 to $5.98 per share. In the first quarter of 2025, Solventum achieved top-line results with robust revenue of $8.3 billion and a solid gross margin of 54.9%.

Solventum Corporation (NYSE:SOLV) is a global healthcare company that was formed following a spin-off from the 3M healthcare business. It develops, manufactures, and commercializes solutions that leverage material science, data science, and digital capabilities to improve healthcare.

While we acknowledge the potential of Solventum Corporation (NYSE:SOLV) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SOLV and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.